Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev).
about
Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev).
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Radiotherapy prolongs the surv ...... side and bevacizumab (mPEBev).
@en
Radiotherapy prolongs the surv ...... omic etoposide and bevacizumab
@nl
type
label
Radiotherapy prolongs the surv ...... side and bevacizumab (mPEBev).
@en
Radiotherapy prolongs the surv ...... omic etoposide and bevacizumab
@nl
prefLabel
Radiotherapy prolongs the surv ...... side and bevacizumab (mPEBev).
@en
Radiotherapy prolongs the surv ...... omic etoposide and bevacizumab
@nl
P2093
P2860
P50
P356
P1433
P1476
Radiotherapy prolongs the surv ...... side and bevacizumab (mPEBev).
@en
P2093
Claudia Gandolfo
Luigi Pirtoli
Paolo Tini
Pierfrancesco Tassone
Pierosandro Tagliaferri
Pierpaolo Pastina
Silvia Zappavigna
Stefania Croci
Veronica Ricci
P2860
P304
75904-75913
P356
10.18632/ONCOTARGET.20411
P407
P50
P577
2017-08-24T00:00:00Z